Last reviewed · How we verify
spironolactone, beta-blockers,ecc
spironolactone, beta-blockers,ecc is a Combination therapy: potassium-sparing diuretic + beta-adrenergic antagonist Small molecule drug developed by University of Roma La Sapienza. It is currently FDA-approved for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.
This is a combination therapy using spironolactone (a potassium-sparing diuretic and aldosterone antagonist) and beta-blockers to reduce fluid retention, lower blood pressure, and decrease cardiac workload.
Spironolactone and beta-blockers are used in the treatment of heart failure and renal insufficiency, as indicated by ClinicalTrials.gov. The exact mechanism of action for spironolactone is not specified in the provided facts, but according to ChEMBL, it is a potassium-sparing diuretic that acts as an antagonist of the mineralocorticoid receptor.
At a glance
| Generic name | spironolactone, beta-blockers,ecc |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Drug class | Combination therapy: potassium-sparing diuretic + beta-adrenergic antagonist |
| Target | Aldosterone receptor (mineralocorticoid receptor) and beta-adrenergic receptors (β1, β2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Spironolactone blocks aldosterone receptors in the collecting duct, promoting sodium and water excretion while retaining potassium, thereby reducing blood volume and blood pressure. Beta-blockers reduce heart rate and contractility, decreasing cardiac oxygen demand and blood pressure. Together, these agents are commonly used in heart failure and hypertension management to improve outcomes and reduce neurohormonal activation.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Post-myocardial infarction management
- Aldosteronism
Common side effects
- Hyperkalemia
- Fatigue
- Dizziness
- Bradycardia
- Gynecomastia (spironolactone)
- Hypotension
- Erectile dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- spironolactone, beta-blockers,ecc CI brief — competitive landscape report
- spironolactone, beta-blockers,ecc updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI
Frequently asked questions about spironolactone, beta-blockers,ecc
What is spironolactone, beta-blockers,ecc?
How does spironolactone, beta-blockers,ecc work?
What is spironolactone, beta-blockers,ecc used for?
Who makes spironolactone, beta-blockers,ecc?
What drug class is spironolactone, beta-blockers,ecc in?
What development phase is spironolactone, beta-blockers,ecc in?
What are the side effects of spironolactone, beta-blockers,ecc?
What does spironolactone, beta-blockers,ecc target?
Related
- Drug class: All Combination therapy: potassium-sparing diuretic + beta-adrenergic antagonist drugs
- Target: All drugs targeting Aldosterone receptor (mineralocorticoid receptor) and beta-adrenergic receptors (β1, β2)
- Manufacturer: University of Roma La Sapienza — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Hypertension
- Indication: Drugs for Post-myocardial infarction management
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing